drugset / Trial / NCT03421756
Stem Cell Transplant in Patients With Severe Sickle Cell Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective pilot study of matched-related donor allogeneic stem cell transplantation in adults with severe sickle cell disease using a matched-sibling PBSC graft with a non-myeloablative conditioning regimen (Alemtuzumab).
Timeline
- Start
- 2018-03-29
- Primary completion
- 2018-09-15
- Completion
- 2022-05-15
Outcome
Outcome not reported
Stopped (Enrollment): “Trial terminated due to low rate of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Alemtuzumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Background | Sirolimus | Small molecule | — | — |